Tuesday, February 12th, 12:00pm – 12:55pm
The pipeline for Chronic Lymphocytic Leukemia (CLL) gained a lot of attention at ASH 2012, with several promising new therapies in development. Although 70-80% of treatment naïve patients respond to first-line fludarabine regimens, patients still ultimately progress, leaving room for other alternatives. BTK and PI3K inhibitors are showing great promise in clinical trials, especially when used in combination with existing therapies. We know what investors are saying, but what therapies do the clinicians on the front lines think will revolutionize the space? Join us for an all-physician panel of KOLs discussing the CLL Chronicles—past, present and future. Discussion will focus on what has been tried, what are the best options now and what are the potential game-changers in the future and will include an interactive Q&A with the audience.
- Joel Sendek, Managing Director, Stifel Nicolaus
- Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of Medicine CLL Research and Treatment Program
- John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center
Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine
Jacqueline Barrientos, MD
John F. Gerecitano, MD, PhD
John Gerecitano is a medical oncologist/hematologist who cares for patients with lymphoma. He has clinical expertise in both Hodgkin and non-Hodgkin lymphoma. His research interests focus on finding new treatments for patients with lymphoma. To accomplish this goal, Dr. Gerecitano serve as the principal investigator on several phase I and phase II clinical trials aimed at bringing promising new treatments from laboratories around the world into early clinical trials. Many of his trials explore innovative ways to combine existing drugs with newer treatments in order to find novel ways to advance the care of patients with lymphoma. He am also a member of the Developmental Therapeutics Group — a team of medical oncologists dedicated to providing access to the newest phase I agents for patients with all types of cancer throughout the Memorial Sloan-Kettering system.
Kanti Rai, MD
Kanti R. Rai, MD, was born in Jodhpur, India, and received his medical education in Jaipur, India. After residency training in pediatrics and Fellowship in hematology and nuclear medicine in hospitals in New York, he joined the hematopoietic cell-kinetic research team led by Dr. Eugene Cronkite at the Brookhaven National Laboratory in Long Island, NY. Interest in the study of lymphocyte biology and in chronic lymphocytic leukenia (CLL) soon followed in the early 1960's, with collaboration with his two mentors, Dr. Cronkite and Dr. Arthur Sawitsky. This collaboration led to the development of the system of clinical staging of CLL. Dr. Rai has continued to remain in the forefront of research in the studies of natural history of CLL, improving prognostic features and in the development of newer strategies of therapy which are hypothesis-driven.
Dr. Rai is an active investigator in the Chronic Lymphocytic Leukemia Research Consortium (CRC), the International Workshop on CLL (IWCLL), and Cancer and Leukemia Group B (CALGB). He is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the American Society of Hematology (ASH). In 2006, Dr. Rai served as the President of ASH. He is the Joel Finkelstein Cancer Foundation Professor of Medicine, and Professor of Molecular Medicine at the Hofstra North Shore-LIJ School of Medicine at Hofstra University.
Joel Sendek is a Managing Director and Biotechnology Analyst at Stifel, Nicolaus & Company. He is also Group Head of the Healthcare Equity Research at Stifel. He has been a senior biotechnology analyst for 15 years with coverage that spans both large-cap and small-cap companies. Prior to joining Stifel, Joel was a Managing Director and biotechnology analyst for 11 years at Lazard Capital Markets, where he established Lazard's healthcare equity research effort in 2000. Prior to Lazard he was a Senior Vice President and biotechnology research analyst at Gerard Klauer Mattison. He has been recognized by the Wall Street Journal as an All-Star Analyst with a #1 ranking for stock picking in biotechnology as well as first place in the "Home Run Hitter" category among all sectors. From 1992 to 1997, Joel served as Senior Director of Corporate Development at Progenics Pharmaceuticals, where he negotiated corporate partnerships, raised private equity capital and prepared the company for an IPO. Prior to Progenics, he worked in the corporate finance department at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992. Joel received a Bachelor of Arts in Biochemistry from Rice University.